Additionally, Ile-52 and Glu-64 were generally maintained as either hydrophobic or polar residues across GST classes [82]
Other Ingredients: Calcium carbonate, microcrystalline cellulose (plant fiber), stearic acid, magnesium stearate, aqueous film-coating (purified water, hydroxypropyl methylcellulose, vegetable glycerin), silica
All dosing is individualized: the ranges here represent typical physician-prescribed ranges, not a standard or approved protocol
Standard PA criteria across payers typically include: Confirmed diagnosis of primary hyperlipidemia or HeFH or HoFH with supporting ICD-10 code Documented LDL-C level above payer-specified threshold (commonly 70 mg/dL or 100 mg/dL depending on cardiovascular risk category) Evidence of maximally tolerated statin therapy or documented statin intolerance Prescribing clinician is a cardiologist, lipidologist, or relevant specialist (some plans require specialist involvement) Previous trial of other LDL-lowering therapies (PCSK9 inhibitors or ezetimibe, plan-specific) Maintaining thorough PA documentation in secure patient records is essential for both initial approvals and denial appeals
indicates increase/upregulation and indicates decrease/downregulation
The capsules contain: Only active Beneficial Ingredients, No Additives, Fillers, Contaminants, Soaps, Industrial Lubricants or Colorants
,aspect=ignore)
